Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC

Prostate cancer (PCa) remains the most diagnosed non-skin cancer amongst the American male population. Treatment for localized prostate cancer consists of androgen deprivation therapies (ADTs), which typically inhibit androgen production and the androgen receptor (AR). Though initially effective, a...

Full description

Bibliographic Details

Main Authors:	Ralph E. White, Maxwell Bannister, Abderrahman Day, Hannah E. Bergom, Victor M. Tan, Justin Hwang, Hai Dang Nguyen, Justin M. Drake
Format:	Artigo
Language:	Inglês
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Oncology
Subjects:	prostate cancer enzalutamide SRC kinase inhibitor Synergy androgen receptor phosphorylation
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1210487/full
Tags:	Add Tag No Tags, Be the first to tag this record!